Core Insights - Tevogen Bio Holdings Inc. expresses gratitude to the U.S. Department of Health and Human Services for addressing Long COVID through roundtables focused on patient experiences and research [1] - Approximately 20 million adults in the U.S. are affected by Long COVID, leading to significant economic consequences due to workforce absenteeism and productivity losses [2] - Tevogen's investigational drug, TVGN 489, shows promising results in clinical trials and may play a crucial role in addressing the Long COVID public health crisis [3] Company Developments - The CEO of Tevogen emphasizes the importance of addressing the lasting consequences of SARS-CoV-2, highlighting the potential of TVGN 489 to restore health for those affected by Long COVID [4] - Tevogen is committed to developing accessible and affordable personalized therapeutics through its ExacTcell™ platform, which focuses on precision T cell therapies [4]

Core Insights - Tevogen Bio Holdings Inc. will have its Chief Information Officer, Mittul Mehta, participate in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025 [2][3] - The Startup Forum will focus on insights from venture capital leaders and early-stage innovators regarding scaling companies with Databricks [3] Company Participation - Mittul Mehta will join industry peers such as Chris Gervais, CTO of Codametrix, and Stavros Papadopoulos, CEO of TileDB, in a discussion moderated by Tony Pezzullo, Principal at SignalFire [3] - Mehta will discuss Tevogen.AI's use of advanced data and AI technologies, particularly the PredicTcell™ platform, which was developed in collaboration with Microsoft and Databricks to enhance precision immunotherapy development [3] Event Details - The Databricks DATA + AI World Tour will be held at the Sheraton Boston Hotel [4]

Core Insights - Tevogen Bio Holdings Inc. estimates the risk-adjusted Net Present Value (rNPV) for its product TVGN 116, aimed at liver cancer prevention in high-risk chronic Hepatitis B patients, to exceed approximately $325 million in the US alone [1][3] - The cumulative 5-year top-line revenue forecast for TVGN 116 is projected to be around $6.5 billion, reflecting the company's innovative and efficient drug development model [2] Financial Projections - The current rNPV for TVGN 116 is based on the understanding of unmet medical needs and the competitive landscape, with adjustments made at each milestone in the product development lifecycle [3] - Tevogen's progress with its first clinical-stage product, TVGN 489, demonstrates the rapid achievement of development milestones [3] Strategic Outlook - The company’s drug development model is positioned as a potential blueprint for sustainable medical innovation in the future [2]

Core Insights - Tevogen Bio Holdings Inc. estimates the risk-adjusted net present value (rNPV) of its product TVGN-489 to be between $9 billion and $11 billion, targeting treatment for SARS-CoV-2 and Long-COVID in high-risk patients [1][3] Clinical Trial Findings - In a Phase I proof-of-concept trial, two cancer patients received TVGN-489 and were able to proceed to stem cell transplants shortly after treatment, with no complications from COVID-19 observed [2] - High-risk ambulatory patients showed significant viral elimination, with ≥88% of patients achieving viral clearance by Day 4 and >99% by Day 14 [7] - No disease progression or recurrent COVID-19 cases were reported in the treatment arm during a six-month follow-up [7] Revenue Projections - Tevogen's cumulative revenue projections for TVGN-489 over five years indicate a strong market potential, with the rNPV reflecting only U.S. revenue potential and not the broader ExacTcell™ technology platform [3][4] Future Plans - The company plans to provide ongoing updates regarding the valuation of its internally developed assets, including product pipeline developments [4]

Core Insights - Tevogen Bio Holdings Inc. has announced the potential value and forecast for its pipeline product, TVGN 930, aimed at treating non-solid tumor malignancies associated with Epstein-Barr Virus (EBV) [1][2] Financial Projections - The cumulative 5-year top-line revenue forecast for TVGN 930 is approximately $3.5 billion, reflecting the company's innovative drug development model [2] - The risk-adjusted Net Present Value (rNPV) for TVGN 930 is projected to exceed $250 million in the US alone [7] Market Opportunity - There are currently no approved vaccines for EBV, creating a significant therapeutic gap that TVGN 930 aims to fill [4] - The accessible market in the US for TVGN 930 could potentially cover up to 40,000 patients across five rare disease indications [7] Additional Applications - The treatment of multiple sclerosis through tighter EBV control presents an additional opportunity for the product [3]

Core Viewpoint - Tevogen Bio Holdings Inc. emphasizes the ongoing need for effective SARS-CoV-2 treatments, particularly for individuals with weakened immune systems, highlighting the potential of its investigational therapy TVGN 489 to enhance immunity and eliminate the virus [1][3] Group 1: Product Development and Clinical Trials - TVGN 489 is an allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte immunotherapy developed using the ExacTcell platform, targeting the entire viral genome rather than just a single protein [1] - Positive clinical trial data indicates that in the treatment arm, viral elimination reached over 99% in all patients by day 14, with no disease progression or Long COVID observed [6] - The treatment was well-tolerated across all dose levels, and CTLs persisted in treated patients for up to six months, suggesting a durable immune response [6] Group 2: Market Context and Challenges - The emergence of the XFG variant of SARS-CoV-2 underscores the ongoing threat of COVID-19, particularly for vulnerable populations, necessitating continuous surveillance and treatment efforts [3] - The company acknowledges the challenges posed by mutation-prone viruses, indicating that targeting only the spike protein is insufficient for effective treatment [3] Group 3: Future Outlook - Tevogen's leadership expresses confidence in the potential of TVGN 489 to provide necessary immune support for high-risk patients, emphasizing the importance of innovative therapies in the face of evolving viral threats [3]

Core Insights - Tevogen Bio Holdings Inc. has significant internally developed assets that are not reflected on its balance sheet but represent substantial long-term value [1][3] - The company plans to provide detailed information and valuation of these assets in the near future [1] Asset Overview - Key assets include PredicTcell™, which utilizes AI algorithms to predict peptide–T cell receptor interactions, thereby accelerating development and expanding the pipeline [1] - AdapTcell™ employs AI models to decode HLA–T cell interactions, enhancing immune system insights and revealing new therapeutic paths [2] Intellectual Property and Technology - Tevogen holds three granted U.S. patents and has twelve pending U.S. patents, including two related to artificial intelligence [6] - The company has strategic collaborations with Microsoft and Databricks to support its AI technology [6] Drug Development and Clinical Pipeline - The ExacTcell™ platform focuses on highly purified, target-specific CD8+ cytotoxic T lymphocytes (CTL) [6] - The clinical pipeline includes therapeutics designed to treat cancers while allowing patients to continue oncology care, with potential expansion into non-oncology indications [6] Financial Position - Tevogen has access to a line of credit and is well-capitalized for current operations [6] - The company is establishing internal GMP manufacturing capabilities [6] Facilities - Tevogen operates a drug discovery lab in Philadelphia and has its headquarters in New Jersey [6]

Core Insights - Tevogen Bio Holdings Inc. has been recognized by Yale University for its commitment to health equity and the leadership of its Founder and CEO, Dr. Ryan Saadi [2] - The company operates with a lean, capital-efficient business model, fully owning its core intellectual property to minimize costs and complexity in developing CD8+ T cell therapies [3] - Dr. Saadi emphasized that affordability and accessibility are foundational to Tevogen's operations, achieving significant milestones with lower capital expenditure compared to industry norms [4] Business Model and Strategy - Tevogen's business model is designed to withstand market pressures through a capital-efficient structure, focusing on off-the-shelf, genetically unmodified therapies [3] - The company has avoided the typical billion-dollar burn rate seen in the industry, maintaining a lean cash run rate while preserving equity [4] - Tevogen aims to deliver innovative therapies that not only improve patient outcomes but also achieve commercial success at a lower cost [4] Recognition and Impact - The recognition from Yale highlights the impact of Tevogen's mission on making healthcare more affordable and accessible [2] - Dr. Saadi's vision is acknowledged as a significant contribution to the healthcare landscape, reinforcing the company's commitment to health equity [2][4]

Core Viewpoint - Tevogen Bio Holdings Inc. has reported a significant increase in institutional ownership of its common stock, indicating growing confidence from long-term investors in the company's scientific and operational progress [2][3]. Institutional Ownership Update - As of June 30, 2025, institutional ownership of Tevogen common stock rose by 24% compared to March 31, 2025, following a 60% increase in the first quarter [2]. - The number of institutional holders increased from 51 to 55, with 72% of these holders either increasing or maintaining their positions [2]. Key Contributors - Major contributors to the second quarter growth in institutional ownership were Morgan Stanley and BlackRock, which collectively increased their holdings by 80% [2]. Management Commentary - The Head of Investor Relations at Tevogen stated that the increase in institutional ownership is a positive sign, reflecting the company's scientific advancements and operational milestones, such as positive clinical data and progress towards internal GMP cell manufacturing capabilities [3].

Core Insights - Tevogen Bio Holdings Inc. has been recognized in BINJE's BEST Health Care 2025 for its commitment to health equity and innovation in sustainable biopharma [1][2] - The company's focus is on developing affordable and safe T cell therapies for acute viral infections and cancers, utilizing its proprietary ExacTcell™ platform [2] Company Overview - Tevogen Bio is dedicated to advancing health equity by ensuring access to life-saving medications through a sustainable biopharma model [2] - The company operates a lean, capital-efficient structure that avoids licensing overhead by fully owning its core intellectual property [2] - Tevogen's CD8+ T cell therapies are designed to reduce manufacturing complexity and costs, aligning with U.S. healthcare priorities [2] Technological Advancements - The launch of Tevogen.AI aims to accelerate therapeutic discovery and development through advanced algorithms and partnerships with Microsoft and Databricks [2] Recognition and Community - Tevogen expresses gratitude to BINJE and congratulates other honorees in the health care sector for their achievements [3]